307 related articles for article (PubMed ID: 34103181)
1. Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
Courcier J; Dalban C; Laguerre B; Ladoire S; Barthélémy P; Oudard S; Joly F; Gravis G; Chevreau C; Geoffrois L; Deluche É; Rolland F; Topart D; Culine S; Négrier S; Mahammedi H; Tantot F; Jamet A; Escudier B; Flippot R; Albigès L
Eur Urol; 2021 Sep; 80(3):325-329. PubMed ID: 34103181
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E; Dalban C; Colomba E; Derosa L; Alves Costa Silva C; Negrier S; Chevreau C; Gravis G; Oudard S; Laguerre B; Barthelemy P; Goupil MG; Geoffrois L; Rolland F; Thiery-Vuillemin A; Joly F; Ladoire S; Tantot F; Escudier B; Albiges L
Clin Genitourin Cancer; 2022 Oct; 20(5):488-494. PubMed ID: 35977881
[TBL] [Abstract][Full Text] [Related]
4. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Billon E; Dalban C; Oudard S; Chevreau C; Laguerre B; Barthélémy P; Borchiellini D; Geoffrois L; Negrier S; Joly F; Thiery-Vuillemin A; Gross-Goupil M; Rolland F; Priou F; Mahammedi H; Tantot F; Escudier B; Chabaud S; Albiges L; Gravis G
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37813745
[TBL] [Abstract][Full Text] [Related]
5. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Flippot R; Dalban C; Laguerre B; Borchiellini D; Gravis G; Négrier S; Chevreau C; Joly F; Geoffrois L; Ladoire S; Mahammedi H; Rolland F; Gross-Goupil M; Deluche E; Priou F; Laramas M; Barthélémy P; Narciso B; Houedé N; Culine S; Oudard S; Chenot M; Tantot F; Chabaud S; Escudier B; Albiges L
J Clin Oncol; 2019 Aug; 37(23):2008-2016. PubMed ID: 31194611
[TBL] [Abstract][Full Text] [Related]
7. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Carril-Ajuria L; Desnoyer A; Meylan M; Dalban C; Naigeon M; Cassard L; Vano Y; Rioux-Leclercq N; Chouaib S; Beuselinck B; Chabaud S; Barros-Monteiro J; Bougoüin A; Lacroix G; Colina-Moreno I; Tantot F; Boselli L; De Oliveira C; Fridman WH; Escudier B; Sautes-Fridman C; Albiges L; Chaput-Gras N
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640928
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M; Dalban C; Chevreau C; Gravis G; Negrier S; Laguerre B; Gross-Goupil M; Ladoire S; Borchiellini D; Geoffrois L; Joly F; Priou F; Barthelemy P; Laramas M; Narciso B; Thiery-Vuillemin A; Berdah JF; Ferrari V; Dominique Thomas Q; Mione C; Curcio H; Oudard S; Tantot F; Escudier B; Chabaud S; Albiges L; Thibault C
Eur J Cancer; 2023 Mar; 182():66-76. PubMed ID: 36746010
[TBL] [Abstract][Full Text] [Related]
9. Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
Guilhem-Ducléon G; Dalban C; Negrier S; Gravis G; Laguerre B; Chevreau C; Oudard S; Barthelemy P; Ladoire S; Boughalem E; Borchiellini D; Linassier C; Nenan S; Flippot R; Albiges L; Goupil MG
Clin Genitourin Cancer; 2023 Dec; 21(6):643-652. PubMed ID: 37635052
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Mourey L; Rainho LT; Dalban C; Carril-Ajuria L; Negrier S; Chevreau C; Gravis G; Thibault C; Laguerre B; Barthelemy P; Borchiellini D; Gross-Goupil M; Geoffrois L; Rolland F; Thiery-Vuillemin A; Tantot F; Chaput N; Naigeon M; Teixeira M; Escudier B; Flippot R; Albiges L
Eur J Cancer; 2024 Apr; 201():113589. PubMed ID: 38382153
[TBL] [Abstract][Full Text] [Related]
13. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
17. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
[TBL] [Abstract][Full Text] [Related]
18. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Carril-Ajuria L; Lavaud P; Dalban C; Negrier S; Gravis G; Motzer RJ; Chevreau C; Tannir NM; Oudard S; McDermott DF; Laguerre B; Hammers HJ; Barthelemy P; Plimack ER; Borchiellini D; Gross-Goupil M; Jiang R; Lee CW; de Silva H; Rini BI; Escudier B; Albigès L
Eur J Cancer; 2024 Jun; 204():114048. PubMed ID: 38653033
[TBL] [Abstract][Full Text] [Related]
19. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
